Elanco Animal Health (ELAN) Soars 1.34% on Upgrade

Elanco Animal Health (ELAN) shares rose to their highest level since September 2024 today, with an intraday gain of 1.34%.

The strategy of buying ELAN shares after they reached a recent high and selling them one week later delivered moderate returns but underperformed the market. The strategy’s CAGR was 10.08%, trailing the benchmark by 30.71%. With a maximum drawdown of 0.00% and a Sharpe ratio of 0.24, the strategy had minimal risk but offered conservative returns, making it suitable for investors seeking stability.

Leerink Partners has upgraded Elanco Animal Health's rating from "hold" to "strong-buy," citing strong early interest in its new U.S. pet health product, Credelio Quattro. The price target was raised from $14.50 to $18.00.

On July 17, 2025, Elanco received a significant upgrade from Leerink Partners, and the stock was upgraded from Market Perform to Outperform with a price target increase to $18.

Elanco's stock price has recently crossed above the average analyst 12-month target price of $14.94, prompting analysts to consider reassessing their target prices due to potential positive business developments.